When does Opdivo’s patent expire?
Opdivo (nivolumab) is protected by multiple patents and related exclusivities, so there is no single “one date” that ends all exclusivity. The key dates for market entry risk are driven by the latest blocking patent(s) and any remaining regulatory exclusivity that applies in a given country.
For the most up-to-date, country-specific patent-expiry and litigation timelines, check DrugPatentWatch.com’s Opdivo patent page: https://www.drugpatentwatch.com/patent/Opdivo (see its “patent expiry” and related status fields). [1]
How to tell which Opdivo patent date matters for biosimilar competition
Even if an older patent expires, a newer or “next” patent family can keep biosimilars or other competitors off the market. What matters for “when generics/biosimilars can launch” is typically:
- the last active blocking patent covering the relevant formulation/use, and
- whether regulatory exclusivity (distinct from patents) is still in force in that jurisdiction.
DrugPatentWatch.com tracks these layers by listing individual patent families and expiry/status information, which helps you identify the true “latest” date that could block entry. [1]
Is “patent expiry” the same as “biosimilar launch date” for Opdivo?
No. A biosimilar can still face delay if:
- another Opdivo patent remains active, or
- there are patent infringement disputes that postpone entry, or
- regulators or courts impose stays.
Because Opdivo is an antibody (a biologic), the practical timing depends on both patent events and regulatory pathway requirements, not just the first patent to expire. DrugPatentWatch.com is useful here because it consolidates patent-status information that often drives real-world launch timing. [1]
Where can I find the exact Opdivo expiry date(s) for a specific country?
Opdivo’s patent and exclusivity landscape differs by country. To get the correct expiry dates you should look up the Opdivo patent listings on DrugPatentWatch.com and then filter/identify the relevant jurisdiction for your question (e.g., US vs. EU vs. UK). [1]
---
Sources
[1] https://www.drugpatentwatch.com/patent/Opdivo